We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Global Chemiluminescence Immunoassay Market Driven by Increasing Incidence of Diseases and Technological Advancements

By LabMedica International staff writers
Posted on 14 Sep 2023
Print article
Image: The global chemiluminescence immunoassay market is expected to reach USD 19 billion by 2028 (Photo courtesy of 123RF)
Image: The global chemiluminescence immunoassay market is expected to reach USD 19 billion by 2028 (Photo courtesy of 123RF)

Chemiluminescence immunoassays are crucial for the accurate diagnosis and management of infectious diseases such as HIV/AIDS, hepatitis, respiratory issues, and sexually transmitted infections. This vital role in disease management is acting as a key growth driver of the global chemiluminescence immunoassays market which is expected to register a CAGR of 7.5% from approximately USD 13.2 billion in 2023 to USD 19 billion by 2028. The need for accurate and timely diagnosis of these diseases in order to enable their effective treatment and control is expected to continue driving market growth.

These are the latest findings of Research and Markets (Dublin, Ireland), a leading source for international market research reports and market data.

By sample type, the blood samples segment is projected to witness the highest growth in the chemiluminescence immunoassay market during the forecast period, driven primarily by the increasing number of blood donations and rising incidence of chronic and infectious diseases. Based on application, the oncology testing segment is projected to register the highest growth in the chemiluminescence immunoassay market during the forecast period. This can be attributed to the surge in demand for oncology testing as a result of a rise in the incidence of cancer, increasing emphasis on the need for early detection and treatment of cancer, alongside measures to expand cancer screening measures.

Geographically, the chemiluminescence immunoassay market in Asia Pacific is poised to register the highest CAGR during the forecast period. Countries such as China and India have been investing heavily in healthcare infrastructure development and have a substantial target population. These factors are expected to generate strong growth prospects for companies operating in the chemiluminescence immunoassay market in this region.

Related Links:
Research and Markets

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.